June 6, 2014 / 6:22 AM / 5 years ago

BRIEF-GW Pharma receives FDA fast-track designation for Dravet syndrome treatment

June 6 (Reuters) - GW Pharmaceuticals Plc :

* Announces epidiolex receives fast-track designation from FDA for treatment of dravet syndrome

* Expects to hold pre-IND meeting with FDA for epidiolex in treatment of LGS in mid-2014, and expects to conduct two phase 3 trials in LGS during 2015 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below